

Tumores do Sistema Nervoso Central

Temozolomida + Radioterapia

Temozolomida: 75 mg/m² VO ou IV por 6 semanas concomitante a radioterapia, seguido por 150 mg/m² VO D1–5 a cada 28 dias

Dose da Temozolomida após a radioterapia: 150 a 200 mg/m² VO D 1-5 a cada 28 dias. Ref. (1) e Ref. (9)

PCV

Procarbazina: 60 mg/m² VO D8–21

Lomustina: 110 mg/m² VO D1

Vincristina: 1.4 mg/m² IV D8 e 29

a cada 6 a 8 semanas por 6 a 7 ciclos (2).

BCNU

BCNU: 200 mg/m² IV D1

a cada 6–8 semanas por um ano

Ref. (3,4,10)

OU

BCNU: 75–100 mg/m² IV D1 e 2

a cada 6–8 semanas

Ref. (3)

Procarbazina

Procarbazina: 150 mg/m² VO diariamente dividido em 3 doses.

Ref. (5)

Temozolomida

Temozolomida: 150 mg/m² VO ou IV D1–5

a cada 28 dias

Ref. (6)

Irinotecano

Irinotecano: 350 mg/m² IV em 90 min D1
a cada 3 semanas Ref. (7)

OU

Irinotecano: 125 mg/m² IV semanalmente por 4 semanas
a cada 6 semanas Ref. (8)

ACE

Carboplatina: AUC 5 IV D1
Etoposide: 100mg/m² IV D1 a D3
Bevacizumabe: 10mg/kg IV D2
a cada 3 semanas Ref. (11)

BCE

BCNU: 200mg/m² IV D1
Cisplatina: 20mg/m² IV D1 a D5
Etoposide: 100mg/m² IV D1 a D5
a cada 5 semanas, seguido por radioterapia Ref. (12)

Temozolamida + Cisplatina

Temozolamida: 200 mg/m²/dia VO ou IV por 5 dias
Cisplatina: 100mg/m² IV D1 Ref. (13)

Cisplatina + Carmustina

Cisplatina: 100mg/m² IV D1 a cada 21 dias
Carmustina: 160mg/m² IV D2 a cada 42 dias Ref. (14,15)

Temozolamida + Cisplatina

Cisplatina: 75mg/m² IV D1
Temozolamida: 150mg/m² VO ou IV D1 a D5 a cada 21 dias
Ref. (16)

Bevacizumabe + Irinotecano

Bevacizumabe: 10mg/kg IV

Irinotecano: 125mg/m² IV (se paciente não usando antiepiléptico)
ou 340mg/m² IV (se paciente usando antiepiléptico)

a cada 15 dias

Ref. (17, 18)

1. Stupp R, *et al.* Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005; 352: 987–995.
2. Levin VA, *et al.* Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, evincristine (PCV) over BCNU poranaplastic gliomas: NCOG 6G61 final report. *Int J Radiat Oncol Biol Phys* 1990; 18:321–324.
3. DeAngelis LM, *et al.* Malignant gliomas: who benefits from adjuvant chemotherapy? *Ann Neurol* 1998; 44:691–695.
4. Buckner JC, *et al.* Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy associations with chromosomal abnormalities. *J Clin Oncol* 2003; 21: 251–255.
5. Yung A, *et al.* Randomized trial of temozolomide (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. *Proc Am Soc Clin Oncol* 1999; 18:139a.
6. Yung A, *et al.* Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. *J Clin Oncol* 1999; 17: 2762–2771.
7. Raymond E, *et al.* Multicenter phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. *Ann Oncol* 2003; 14: 603–614.
8. Friedman H, *et al.* Irinotecan therapy in adults with recurrent or progressive malignant glioma. *J Clin Oncol* 1999; 17: 1516–1525.

9. Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol.* 2009 Mar 6.
10. Stewart LA . Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. *Lancet* 2002 Mar 23; 359(9311):1011-8.
11. Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, Lickliter JD. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. *J Clin Neurosci.* 2010 Aug; 17(8): 970-4.
12. Lassen U, Kristjansen PE, Wagner A, Kosteljanetz M, Poulsen HS. Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. *J Neurooncol.* 1999 Jun; 43(2):161-6.
13. Balaña C, López-Pousa A, Berrocal A, Yaya-Tur R, Herrero A, García JL, Martín-Broto J, Benavides M, Cerdá-Nicolás M, Ballester R, Balart J, Capellades J. Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). *J Neurooncol.* 2004 Dec;70(3):359-69.
14. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR; North Central Cancer Treatment Group 93-72-52; Southwest Oncology Group 9503 Trials Phase III trial of carmustine and cisplatin compared with

carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. *J Clin Oncol.* 2006 Aug 20;24(24):3871-9.

- 15.** Silvani A, Gaviani P, Lamperti EA, Eoli M, Falcone C, Dimeco F, Milanese IM, Erbetta A, Boiardi A, Fariselli L, Salmaggi A. Cisplatin and BCNU chemotherapy in primary glioblastoma patients. *J Neurooncol.* 2009 Aug;94(1): 57-62. Epub 2009 Feb 11.
- 16.** Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D. A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. *Anticancer Res.* 2009 Oct; 29(10): 4275-9.
- 17.** Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. *J Clin Oncol.* 2007 Oct 20; 25(30): 4722-9.
- 18.** Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. *J Clin Oncol.* 2009 Feb 10;27(5):740-5. Epub 2008 Dec 29.